Department of Nephrology and Transplantation, Strasbourg University Hospital, INSERM, UMR-S 1109, Strasbourg, France.
Department of Nephrology and Transplantation, Hôpital Universitaire Necker, APHP Center, Université de Paris INEM INSERM U 1151, CNRS UMR 8253, Paris, France.
Am J Transplant. 2021 Mar;21(3):1295-1303. doi: 10.1111/ajt.16424. Epub 2021 Jan 28.
There are no studies which have compared the risk of severe COVID-19 and related mortality between transplant recipients and nontransplant patients. We enrolled two groups of patients hospitalized for COVID-19, that is, kidney transplant recipients (KTR) from the French Registry of Solid Organ Transplant (n = 306) and a single-center cohort of nontransplant patients (n = 795). An analysis was performed among subgroups matched for age and risk factors for severe COVID-19 or mortality. Severe COVID-19 was defined as admission (or transfer) to an intensive care unit, need for mechanical ventilation, or death. Transplant recipients were younger and had more comorbidities compared to nontransplant patients. They presented with higher creatinine levels and developed more episodes of acute kidney injury. After matching, the 30-day cumulative incidence of severe COVID-19 did not differ between KTR and nontransplant patients; however, 30-day COVID-19-related mortality was significantly higher in KTR (17.9% vs 11.4%, respectively, p = .038). Age >60 years, cardiovascular disease, dyspnea, fever, lymphopenia, and C-reactive protein (CRP) were associated with severe COVID-19 in univariate analysis, whereas transplant status and serum creatinine levels were not. Age >60 years, hypertension, cardiovascular disease, diabetes, CRP >60 mg/L, lymphopenia, kidney transplant status (HR = 1.55), and creatinine level >115 µmol/L (HR = 2.32) were associated with COVID-19-related mortality in univariate analysis. In multivariable analysis, cardiovascular disease, dyspnea, and fever were associated with severe disease, whereas age >60 years, cardiovascular disease, dyspnea, fever, and creatinine level>115 µmol/L retained their independent associations with mortality. KTR had a higher COVID-19-related mortality compared to nontransplant hospitalized patients.
目前尚无研究比较移植受者和非移植患者发生严重 COVID-19 及相关死亡率的风险。我们纳入了两组因 COVID-19 住院的患者,即来自法国实体器官移植登记处的肾移植受者(KTR)(n=306)和单中心队列的非移植患者(n=795)。我们对年龄和严重 COVID-19 或死亡率的危险因素相匹配的亚组进行了分析。严重 COVID-19 的定义为入住(或转入)重症监护病房、需要机械通气或死亡。与非移植患者相比,移植受者更年轻,合并症更多。他们的肌酐水平更高,急性肾损伤发作更多。匹配后,KTR 和非移植患者 30 天严重 COVID-19 的累积发生率无差异;然而,KTR 的 30 天 COVID-19 相关死亡率显著更高(分别为 17.9%和 11.4%,p=0.038)。单因素分析显示,年龄>60 岁、心血管疾病、呼吸困难、发热、淋巴细胞减少和 C 反应蛋白(CRP)与严重 COVID-19 相关,而移植状态和血清肌酐水平则无此相关性。年龄>60 岁、高血压、心血管疾病、糖尿病、CRP>60mg/L、淋巴细胞减少、肾移植状态(HR=1.55)和肌酐水平>115µmol/L(HR=2.32)与 COVID-19 相关死亡率在单因素分析中相关。多因素分析显示,心血管疾病、呼吸困难和发热与严重疾病相关,而年龄>60 岁、心血管疾病、呼吸困难、发热和肌酐水平>115µmol/L 与死亡率的独立相关性仍然存在。与非移植住院患者相比,KTR 的 COVID-19 相关死亡率更高。